Nilanjan Ghosh

Gujarat Cancer & Research Institute — India

Medicine · Health Sciences

42h-index10.0kcitations351works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(182), Chronic Lymphocytic Leukemia Research(151), CAR-T cell therapy research(83), Hematopoietic Stem Cell Transplantation(24), Acute Lymphoblastic Leukemia research(22)

Publications351 total

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma
Blood Advances·2025Open Access
Real-World Evidence on Ibrutinib in First-Line Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma: A Comprehensive Review
Clinical Lymphoma Myeloma & Leukemia·2025Open Access
Treatment patterns and outcomes of primary central nervous system lymphoma treated with high-dose methotrexate with or without autologous stem cell transplantation or whole brain radiation in the rea-world setting
Blood·2025
Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience
Blood·2025Open Access
Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers
Blood·2025Open Access
Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma
Blood·2025
Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study
Blood·2025
Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.
Blood·2025Open Access
Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma
Blood·2025Open Access
Rare Primary Osseous Kaposiform Hemangioendothelioma Treated with Maternal Fibular Allograft: A Case Report and Review
Asian Journal of Case Reports in Surgery·2025
ORAL ABSTRACT: MCL-1493 Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL)
Clinical Lymphoma Myeloma & Leukemia·2025
MCL-1493: Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL)
Clinical Lymphoma Myeloma & Leukemia·2025· 2 cited
POSTER: MCL-1493 Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL)
Clinical Lymphoma Myeloma & Leukemia·2025
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Blood·2025· 10 cited
EE436 Real World Healthcare Resource Utilization (HRU) and Costs Associated With Mantle Cell Lymphoma (MCL) Therapies in the Frontline (1L) and Relapsed/Refractory (R/R) Setting
Value in Health·2025
A Class Focused Marxist Understanding of Financial Capital
Arthaniti-Journal of Economic Theory and Practice·2025
50 | FIXED‐DURATION OUTPATIENT SUBCUTANEOUS MOSUNETUZUMAB + POLATUZUMAB VEDOTIN SHOWS ROBUST EFFICACY IN A PHASE II STUDY OF RELAPSED/REFRACTORY POST‐BTKi MANTLE CELL LYMPHOMA
Hematological Oncology·2025· 1 citedOpen Access
339 | OUTCOMES IN AN INTERNATIONAL MULTICENTRE STUDY OF 600 PATIENTS WITH CNS RELAPSE OF LARGE B CELL LYMPHOMA: COMPARTMENT OF RELAPSE IS PROGNOSTIC
Hematological Oncology·2025Open Access
576 | FIXED‐DURATION SUBCUTANEOUS MOSUNETUZUMAB HAD SIMILAR EFFICACY BUT LOWER CYTOKINE RELEASE SYNDROME RISK VERSUS EPCORITAMAB IN 3L+ FOLLICULAR LYMPHOMA: AN INDIRECT COMPARISON
Hematological Oncology·2025Open Access
280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY
Hematological Oncology·2025· 3 citedOpen Access
page 1 of 18Next →

Frequent Co-authors

Mehdi Hamadani(14), Leo I. Gordon(9), Michael Wang(9), Scott R. Solomon(9), Tanya Siddiqi(9), Timothy S. Fenske(9), Mohamed A. Kharfan‐Dabaja(9), Jonathon B. Cohen(9), Matthew A. Lunning(8), David G. Maloney(8), Kwang Woo Ahn(8), Jeremy S. Abramson(7), Jon Arnason(7), Charalambos Andreadis(7), Alex F. Herrera(7), David J. Inwards(7), Alison R. Sehgal(6), K. OGASAWARA(6), Kenneth L. Wright(6), Narendranath Epperla(6)